(A joint stock company incorporated in the People's Republic of China with limited liability) WARNING The publication of this Application Proof is required by The Stock Exchange of Hong Kong Limited (the "Stock Exchange") and the Securities and Futures Commission (the "Commission") solely for the purpose of providing information to the public in Hong Kong. This Application Proof is in draft form. The information contained in it is incomplete and is subject to change which can be material. By viewing this do ...

Core Viewpoint - Quantum Biopharma Ltd. is facing a class action lawsuit for allegedly misleading investors during the Class Period from January 6, 2021, to October 15, 2025, with claims of stock price manipulation [1][2]. Group 1: Class Action Details - The class action is on behalf of investors who purchased securities during the specified Class Period [1]. - Investors have until February 23, 2026, to file a lead plaintiff motion [1]. Group 2: Allegations Against Defendants - Defendants allegedly entered thousands of spoofed sell orders to create a false appearance of a declining stock price [2]. - These manipulative orders were intended to deceive investors into selling shares at artificially depressed prices [2]. - After driving the market price down, Defendants reportedly purchased Quantum shares at these artificially deflated levels to profit from the scheme [2]. - As a result of these actions, investors were improperly induced to sell their shares at lower prices [2]. Group 3: Legal Representation - The Portnoy Law Firm is representing investors in pursuing claims related to corporate wrongdoing and has a history of recovering over $5.5 billion for aggrieved investors [3].

Core Insights - SEQSTER and Praxis Precision Medicines have expanded their partnership to enhance clinical trials, data collection, and real-world evidence generation for Praxis's clinical development programs [1][2][4] Group 1: Partnership and Collaboration - SEQSTER has been integral to Praxis's clinical trial execution, improving trial enrollment efficiency and capturing necessary longitudinal real-world data [2][3] - The partnership focuses on advancing the ENERGY program, which includes the EMPOWER observational study and POWER clinical studies, attracting over 5,000 patients with epilepsy [3][4] Group 2: Company Profiles - Praxis Precision Medicines is a leading biopharmaceutical company specializing in central nervous system (CNS) disorders, utilizing genetic insights to develop therapies for various neurological conditions [5] - SEQSTER is a healthcare technology company that consolidates patient-consented health data into a unified view, supporting research and patient health management with a repository of 150 million patients [6][7]

Core Insights - Korro Bio, Inc. is recognized as one of the best biotech stocks under $20, with significant potential for investment [1] Company Overview - Korro Bio, Inc. is a biopharmaceutical company focused on developing precision genetic medicines through RNA editing to address both rare and prevalent diseases [4] - The company utilizes its proprietary OPERA platform to advance RNA-editing therapies, which include both clinical and preclinical programs [4] Analyst Upgrades - H.C. Wainwright upgraded Korro Bio, Inc. from Neutral to Buy with a price target of $20, emphasizing the independent value of KRRO-121 as a second risk-mitigated asset [2] - Chardan Capital also upgraded Korro Bio, Inc. from Neutral to Buy with a price target of $15, citing strong preclinical data for KRRO-121 and indicating that the company has "turned the page" [3]

Company Overview - Ardelyx, Inc. (NASDAQ: ARDX) is a biopharmaceutical company focused on developing and commercializing first-in-class gastrointestinal and cardiorenal therapies [3] Financial Updates - TD Cowen raised its price target on ARDX to $13 from $10 while maintaining a Buy rating, following an update to the firm's financial model ahead of ARDX's fourth-quarter results [1] - Jefferies also raised its price target on Ardelyx, Inc. to $15 from $8 and maintained a Buy rating, highlighting the company as one of the most underrated biotech launches [2] Product and Market Potential - Ardelyx's lead product, tenapanor, treats irritable bowel syndrome with constipation (IBS-C) and chronic kidney disease-related conditions [3] - Peak sales for tenapanor are projected at $1.5–$2 billion by 2035, with additional upside if the new 2041 formulation patent proves defendable [2]

Core Insights - CytomX Therapeutics, Inc. (CTMX) is recognized as one of the best biotech stocks under $20, ranking eighth on a compiled list [1] - Analysts have raised price targets for CTMX, indicating positive sentiment ahead of upcoming data releases related to colorectal cancer treatments [2][3] Group 1: Analyst Ratings and Price Targets - Piper Sandler increased its price target on CTMX to $10 from $6.50, maintaining an Overweight rating, citing a 28% overall response rate and a 94% disease control rate from initial Phase 1 data [2] - Barclays analyst raised the price target for CTMX to $8 from $6, also maintaining an Overweight rating, highlighting an attractive risk-reward profile due to imminent readouts on colorectal cancer [3] Group 2: Company Overview - CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing Probody therapeutics, which are designed to enhance cancer targeting and minimize off-tumor toxicity [4] - The company's pipeline includes innovative immuno-oncology and targeted therapies aimed at improving safety and efficacy for solid tumors and other serious diseases [4]

Company Overview - MoonLake Immunotherapeutics (NASDAQ: MLTX) is a clinical-stage biopharmaceutical company focused on developing innovative Nanobody therapies for inflammatory skin and joint diseases. Its main asset, sonelokimab, targets IL-17A and IL-17F to alleviate inflammation in conditions such as hidradenitis suppurativa and psoriatic arthritis [4]. Analyst Ratings - Goldman Sachs downgraded MLTX from Neutral to Sell, raising the price target to $10 from $8. The firm highlighted the advancement of sonelokimab into Phase 3 for palmoplantar pustulosis as a potential opportunity but expressed concerns about significant approvability risks in hidradenitis suppurativa due to the failure of VELA-2 to meet its primary endpoint [2]. - H.C. Wainwright increased the price target for MoonLake Immunotherapeutics to $32 from $26 while maintaining a Buy rating, noting that the outcome of the FDA Type B meeting provides a clear path toward regulatory registration [3]. Investment Considerations - While there is potential for MLTX as an investment, some analysts believe that certain AI stocks present greater upside potential with less downside risk [5].

Group 1 - Nurix Therapeutics, Inc. (NRIX) is ranked second in a list of the 20 Best Biotech Stocks Under $20 to Buy Now [1] - Stifel raised the price target on NRIX to $35 from $33 while maintaining a Buy rating, highlighting 2026 as a crucial year for the company due to two registrational trials and additional Phase 1 updates [1][2] - Wells Fargo lowered the price target on NRIX to $29 from $30 but maintained an Overweight rating, indicating that shares are still considered cheap even without clinical triggers in 2026 [2] Group 2 - Nurix Therapeutics focuses on developing targeted protein modulation therapies using its proprietary DELigase platform, targeting ubiquitin signaling pathways for immunology and oncology [3] - The company aims to develop precision medicines to address unmet medical needs and improve patient outcomes [3]

San Diego, California--(Newsfile Corp. - February 2, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing next-generation sulfur-based prodrugs for rare pediatric diseases, today provided an update on its nephropathic cystinosis program and announced a new investigator-initiated study (IIS) collaboration with Dr. Larry Greenbaum, a recognized global leader in cystinosis research, at Emory University and Childr ...

Company Announcement - Devonian Health Group Inc. has appointed Dennis Turpin as Chief Financial Officer, effective immediately, while he will continue to serve on the Board of Directors [1][3] - Turpin has over 25 years of experience in the biopharmaceutical industry, focusing on finance, capital markets, business development, and mergers and acquisitions [2] - He replaces Viktoria Krasteva, who will assist in the transition until February 27, 2026 [4] Stock Options - A total of 25,000 stock options were granted to Turpin, vesting immediately at an exercise price of $11.50 for a period of 10 years [4] - The company corrected a previous press release regarding the granting of stock options, adjusting the exercise price from $0.18 to $0.19, which is now $11.40 on a post-consolidation basis [5] Company Overview - Devonian Health Group Inc. is a clinical stage pharmaceutical company focused on developing drugs for autoimmune fibroinflammatory diseases, including atopic dermatitis, radiodermatitis, and ulcerative colitis [6] - The company also develops high-value cosmeceutical products and operates a subsidiary, Altius Healthcare LP, for selling prescription pharmaceuticals in Canada [7] - Incorporated in 2015, Devonian is headquartered in Quebec, Canada, and is publicly traded on the TSX Venture Exchange and quoted on the OTCQB Venture Market [8]